Announcement on Voluntary Disclosure of Receiving the Notice of Approval for Clinical Trials of HP515 Tablets for the Treatment of Non-alcoholic Steatohepatitis (NASH)

About this update from Hinova Pharmaceuticals, Inc. Class A

Announcement on Voluntary Disclosure of Receiving the Notice of Approval for Clinical Trials of HP515 Tablets for the Treatment of Non-alcoholic Steatohepatitis (NASH)The abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Hinova Pharmaceuticals, Inc. Class A